Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CIHR Canadian HIV Trials Network | NETWORK |
Not provided
Not provided
Not provided
Not provided
Adherence to antiretroviral therapy (ART) remains problematic. Our team has thus developed a new patient-reported measure of barriers to ART adherence (the I-Score) which will be completed by HIV patients through the Opal patient portal for routine HIV care. This 6-month mixed method pilot study will implement the I-Score/Opal intervention with 5 HIV physicians at the McGill University Health Centre (Montreal, Quebec) and 30 of their patients. The study's primary objectives are to assess patient and physician perceptions of the intervention (e.g., acceptability) and evaluate the implementation strategy. The data collected will help plan and determine the feasibility of a definitive effectiveness trial.
Background: Adherence to antiretroviral therapy (ART) remains problematic. Regular monitoring of its barriers is clinically recommended, however, patient-provider communication around adherence is often inadequate. Our team thus decided to develop a new electronically administered patient-reported outcome measure (PROM) of barriers to ART adherence (the I-Score) to facilitate the systematic capture of this data for physician consideration in routine HIV care. To prepare for a controlled definitive trial to test the I-Score intervention, a pilot study was designed. Its primary objectives are to evaluate patient and physician perceptions of the I-Score intervention and its implementation strategy.
Methods: This one-arm, 6-month study will adopt a mixed method type 3 implementation-effectiveness hybrid design and be conducted at the Chronic Viral Illness Service of the McGill University Health Centre (Montreal, Canada). Five HIV physicians and 30 of their HIV patients with known or suspected adherence problems will participate. The intervention will involve having patients complete the I-Score in the Opal smartphone application, before meeting with their physician. Both patient and physician will have access to the I-Score results, for consideration during the clinic visits at Times 1, 2 (3 months), and 3 (6 months). The implementation strategy will focus on stakeholder involvement, education, and training; promoting the intervention's adaptability; and hiring an Application Manager to facilitate implementation. Implementation, patient, and service outcomes will be collected (Times 1-2-3). The primary outcome is the intervention's acceptability to patients and physicians. Qualitative data obtained, in part, through physician focus groups (Times 2-3) and patient interviews (Times 2-3) will help evaluate the implementation strategy and inform any methodological adaptations.
Discussion: This study will help plan a definitive trial to test the efficacy of the I-Score intervention. It will generate needed data on electronic PROM interventions in routine HIV care that will help improve understanding of conditions for their successful implementation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Opal patient portal | Experimental | Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure | Other | HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months). |
| Measure | Description | Time Frame |
|---|---|---|
| Acceptability of the Intervention as assessed with the Acceptability E-scale | Score range: 6-30 (Threshold: M ≥ 24, indicates high acceptability) | Change from baseline (week 1) to study completion (week 24) |
| Acceptability of the Intervention as indicated by the percent likely to recommend the I-Score | (Threshold: ≥ 80 percent) | Change from baseline (week 1) to study completion (week 24) |
| Acceptability of the Intervention as assessed with the Net Promoter Score | Score range: -100 to 100 (Threshold: > 0, indicates acceptability) | Change from baseline (week 1) to study completion (week 24) |
| Measure | Description | Time Frame |
|---|---|---|
| Appropriateness of the Intervention as assessed with the Perceived Compatibility subscale | Score range: 1 to 7 (Threshold: Score M ≥ 5.5, indicates high compatibility) | Change from baseline (week 1) to study completion (week 24) |
| Appropriateness of the Intervention as assessed with the Appropriateness of Intervention Measure |
| Measure | Description | Time Frame |
|---|---|---|
| Patient management as indicated by the proportion of clinical visits where physicians took action based on I-Score results | Only among visits that identified an adherence barrier of concern with the I-Score PROM | Change from baseline (week 1) to study completion (week 24) |
| Barriers to ART adherence as measured by the I-Score PROM |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bertrand Lebouché, MD | Contact | 514-843-2090 | bertrand.lebouche@mcgill.ca | |
| Kim Engler, PhD | Contact | 514-934-1934 | 32126 | kimcengler@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Bertrand Lebouché, MD | McGill University Health Centre/Research Institute of the McGill University Health Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Institute of the McGill University Health Centre | Montreal | Quebec | H4A3T2 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31376275 | Background | Engler K, Ahmed S, Lessard D, Vicente S, Lebouche B. Assessing the Content Validity of a New Patient-Reported Measure of Barriers to Antiretroviral Therapy Adherence for Electronic Administration in Routine HIV Care: Proposal for a Web-Based Delphi Study. JMIR Res Protoc. 2019 Aug 2;8(8):e12836. doi: 10.2196/12836. | |
| 30375111 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Pilot study with a mixed method type 3 implementation-effectiveness hybrid design
Not provided
Not provided
Not provided
Not provided
|
Score range: 1 to 5 (Threshold: Score M ≥ 4, indicates high appropriateness) |
| Change from baseline (week 1) to study completion (week 24) |
| Feasibility of the Intervention as indicated by the consent rate | Reasons for refusal will also be collected (Threshold: ≥ 70 percent) | At baseline |
| Feasibility of the Intervention as indicated by the retention rate | (Threshold: ≥ 80 percent) | Cumulative until study completion (week 24) |
| Feasibility of the Intervention as indicated by the missing I-Score data rate | e.g., due to non-completion, network failure (Threshold: ≤ 10 percent) | Cumulative until study completion (week 24) |
| Feasibility of the Intervention as assessed with the Feasibility of Intervention Measure | Score range: 1 to 5 (Threshold: M ≥ 4, indicates high feasibility) | Change from baseline (week 1) to study completion (week 24) |
| Fidelity of the Intervention as indicated by the percentage of patients who complete the I-Score on time | (Threshold: ≥ 90 percent) | Cumulative until study completion (week 24) |
| Fidelity of the Intervention as indicated by the percentage of physicians who review the I-Score results on time | (Threshold: ≥ 90 percent) | Cumulative until study completion (week 24) |
| Feasibility of the implementation strategy as indicated by the percentage of physicians who participate in the implementation activities | e.g., educational meeting, focus groups (Threshold: ≥ 80 percent) | Cumulative until study completion (week 24) |
| Feasibility of the implementation strategy as indicated by the number of technical issues encountered | Based on the Application Manager's notes | Cumulative until study completion (week 24) |
Score range: 1 to 20, where higher scores indicate a greater number of problematic barriers |
| Change from baseline (week 1) to study completion (week 24) |
| Adherence to ART as measured by the Self-Rating Scale Item | Score range: 1 to 6, where higher scores indicate higher adherence | Change from baseline (week 1) to study completion (week 24) |
| HIV RNA viral load as indicated in the patient's medical file | Range: Detectable, where > 50 copies/mL = detectable, an undesirable clinical outcome, or Undetectable | Change betweem baseline (week 1) and study completion (week 24) |
| Lessard D, Engler K, Toupin I; I-Score Consulting Team; Routy JP, Lebouche B. Evaluation of a project to engage patients in the development of a patient-reported measure for HIV care (the I-Score Study). Health Expect. 2019 Apr;22(2):209-225. doi: 10.1111/hex.12845. Epub 2018 Oct 29. |
| 30741643 | Background | Kildea J, Battista J, Cabral B, Hendren L, Herrera D, Hijal T, Joseph A. Design and Development of a Person-Centered Patient Portal Using Participatory Stakeholder Co-Design. J Med Internet Res. 2019 Feb 11;21(2):e11371. doi: 10.2196/11371. |
| 34969046 | Derived | Engler K, Vicente S, Ma Y, Hijal T, Cox J, Ahmed S, Klein M, Achiche S, Pant Pai N, de Pokomandy A, Lacombe K, Lebouche B. Implementation of an electronic patient-reported measure of barriers to antiretroviral therapy adherence with the Opal patient portal: Protocol for a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic. PLoS One. 2021 Dec 30;16(12):e0261006. doi: 10.1371/journal.pone.0261006. eCollection 2021. |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |